Kreutzer Jürgen, Fahlbusch Rudolf
Department of Neurosurgery, University of Erlangen, 91054 Erlangen, Germany.
Curr Opin Neurol. 2004 Dec;17(6):693-703. doi: 10.1097/00019052-200412000-00009.
Treatment of pituitary adenomas remains an interdisciplinary challenge involving neurosurgeons, endocrinologists and radiation oncologists. The different disciplines inaugurated advanced techniques to improve the already relatively high standard of outcome for the benefit of patients, covering molecular pathogenesis, novel therapeutic strategies for the different adenoma subtypes, developments in perioperative magnetic resonance imaging and radiosurgical management of pituitary adenomas.
Despite the progress achieved in medical treatment of hormone-secreting pituitary adenomas throughout recent years, surgery remains the primary therapy of choice except for prolactinomas. Recent studies in molecular pathogenesis aiming to find novel therapy targets and reports on new pharmacological drugs effecting GH-secreting pituitary adenomas are reviewed (for example, lanreotide 60, SOM320 and pegvisomant). Advances in surgical treatment of pituitary macroadenomas are obtained by pre- and especially by intraoperative (high-field) MRI offering a higher rate of safe and complete tumor removal. Therapy pitfalls mentioned in the literature throughout the last year as well as key points in the management of pituitary adenomas with focus on acromegaly and Cushing's disease are reported. Adjuvant irradiation for recurrent or residual adenomas is often a necessity. In comparison to standard conventional radiation strategies an increasing number of radiation oncologists and neurosurgeons report their experience with radiosurgery especially for smaller tumor remnants in pituitary adenomas.
Recent molecular studies suggest a new level of complexity in the tumorigenisis of pituitary adenomas in terms of possible cell-type-specific molecular changes. Except for prolactinomas surgery remains the primary treatment for pituitary adenomas. New pharmacological drugs achieve very encouraging endocrine results although no long-term follow-up is available so far. The results of trans-sphenoidal surgery will further improve by modern imaging techniques, especially by applying intraoperative high-field magnetic resonance imaging and neuronavigation. The results of radiosurgical techniques with regard to tumor control are mostly convincing, but definitive conclusions on long-term recurrence and/or late complications are not reliable so far.
垂体腺瘤的治疗仍然是一个跨学科的挑战,涉及神经外科医生、内分泌学家和放射肿瘤学家。不同学科开创了先进技术,以提高已相对较高的治疗效果标准,造福患者,内容涵盖分子发病机制、针对不同腺瘤亚型的新型治疗策略、围手术期磁共振成像的进展以及垂体腺瘤的放射外科治疗。
尽管近年来在分泌激素的垂体腺瘤的药物治疗方面取得了进展,但除催乳素瘤外,手术仍然是主要的治疗选择。本文综述了旨在寻找新治疗靶点的分子发病机制的最新研究以及有关影响生长激素分泌性垂体腺瘤的新药的报道(例如,兰瑞肽60、SOM320和培维索孟)。垂体大腺瘤手术治疗的进展得益于术前尤其是术中(高场)磁共振成像,其能实现更高的安全且完整切除肿瘤的比率。报告了过去一年文献中提到的治疗陷阱以及垂体腺瘤管理的关键点,重点是肢端肥大症和库欣病。对于复发或残留腺瘤,辅助放疗往往是必要的。与标准的传统放疗策略相比,越来越多的放射肿瘤学家和神经外科医生报告了他们在放射外科方面的经验,特别是针对垂体腺瘤中较小的肿瘤残留。
最近的分子研究表明,垂体腺瘤的肿瘤发生在可能的细胞类型特异性分子变化方面具有新的复杂程度。除催乳素瘤外,手术仍然是垂体腺瘤的主要治疗方法。新药取得了非常令人鼓舞的内分泌结果,尽管目前尚无长期随访数据。经蝶窦手术的结果将通过现代成像技术进一步改善,特别是应用术中高场磁共振成像和神经导航。放射外科技术在肿瘤控制方面的结果大多令人信服,但关于长期复发和/或晚期并发症的明确结论目前还不可靠。